News

The Wall Street Journal: FDA, J&J set to announce Baltimore vaccine plant ready to reopen

0

WASHINGTON — The Food and Drug Administration and vaccine maker Johnson & Johnson expect to announce as early as Friday that contamination problems at a COVID-19 vaccine plant in Baltimore are resolved, clearing the way for millions more doses to become available.

Vaccine production at the plant run by contract manufacturer Emergent BioSolutions Inc. 
EBS,
+0.61%

 was halted after unsanitary conditions led to contamination of J&J
JNJ,
-0.15%

vaccines. The facility made vaccine substance and finished vaccine doses for J&J and AstraZeneca 
AZN,
+0.62%

 PLC.

Emergent chief executive Robert Kramer told a House committee last week that the company had produced enough of a key ingredient to yield more than 100 million doses of the J&J vaccine.

The company has been taking corrective measures and been in talks with FDA and J&J over the steps needed to reopen the facility.

An expanded version of this report appears on WSJ.com.

Also popular on WSJ.com:

Why a grand plan to vaccinate the world against COVID unraveled.

The Texas grid came close to an even bigger disaster during February freeze.

The Tell: Investors may be willing to sacrifice returns for ESG — but here’s where they haven’t had to, says Deutsche Bank

Previous article

The Wall Street Journal: Nike dropped soccer star Neymar after sexual-assault allegations

Next article

You may also like

Comments

Leave a reply

Your email address will not be published. Required fields are marked *

More in News